AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference

Core Viewpoint - AtaiBeckley Inc is positioned for growth in 2026 following its strategic combination and redomiciliation, focusing on innovative mental health treatments and engaging with investors at the upcoming J.P. Morgan Healthcare Conference [2][11]. Recent Clinical Updates and Anticipated 2026 Milestones - The company is advancing its pipeline with BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD) and alcohol use disorder, VLS-01 (dimethyltryptamine buccal film) for TRD, and EMP-01 (oral R-MDMA) for social anxiety disorder (SAD) [3][7]. - Topline data from the Phase 2 trial of VLS-01 is expected in the second half of 2026, involving 142 patients with TRD [3]. Recent Corporate Updates - AtaiBeckley reported positive topline data from the Phase 2b trial of BPL-003, showing significant reductions in depressive symptoms with both 8 mg and 12 mg doses compared to a low-dose control [5]. - The company plans to provide guidance on the BPL-003 Phase 3 clinical program in Q1 2026, with trial initiation anticipated in Q2 2026 [5]. - A new patent for EMP-01 was granted, expected to provide exclusivity through 2043, with topline data from the Phase 2a study anticipated in Q1 2026 [6]. Corporate Structure and Market Position - AtaiBeckley was formed through the merger of atai Life Sciences and Beckley Psytech in November 2025, and has redomiciled to the U.S. to streamline operations and align with its shareholder base [11]. - The company’s common stock is now part of the NASDAQ biotechnology index, enhancing its market visibility [11].